Detalhe da pesquisa
1.
Oral estrogen receptor PROTAC® vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models.
Clin Cancer Res
; 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38819400
2.
Regulated Induced Proximity Targeting Chimeras (RIPTACs): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells Selectively.
bioRxiv
; 2023 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36711980
3.
Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer.
Cancer Res
; 62(9): 2468-73, 2002 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-11980634
4.
Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.
J Med Chem
; 57(9): 3856-73, 2014 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-24779514
5.
A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis.
J Am Soc Nephrol
; 14(9): 2237-47, 2003 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12937299